ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jan 2022
Last Updated on 01 Sep 2023
A- A+
Long-acting erythropoiesis-stimulating agents for treating anaemia in chronic kidney disease Guidance is outdated and has been withdrawn on 1 Sep 2023. The Plain English Summary (PES) has been updated on 1 Sep 2023 
 
 



Long-acting erythropoiesis-stimulating agents for treating anaemia in chronic kidney disease (Withdrawn 1 Sep 23) PES Long-acting erythropoiesis-stimulating agents for treating anaemia in chronic kidney disease (Updated 1 Sep 23)